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IMPORTANCE Trastuzumab is a life-saving therapy but is associated with symptomatic and
asymptomatic left ventricular ejection fraction (LVEF) decline. We report the cardiac toxic
effects of a nonanthracycline and trastuzumab-based treatment for patients with early-stage
human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu)-positive
breast cancer.
OBJECTIVE To determine the cardiac safety of paclitaxel with trastuzumab and the utility of
LVEFmonitoring in patients with node-negative, ERBB2-positive breast cancer.
DESIGN, SETTING, AND PARTICIPANTS In this secondary analysis of an uncontrolled, single
group study across 14medical centers, enrollment of 406 patients with node-negative,
ERBB2-positive breast cancer 3 cm, or smaller, and baseline LVEF of greater than or equal to
50% occurred fromOctober 9, 2007, to September 3, 2010. Patients with a micrometastasis
in a lymph node were later allowed with a study amendment. Median patient age was 55
years, 118 (29%) had hypertension, and 30 (7%) had diabetes. Patients received adjuvant
paclitaxel for 12 weeks with trastuzumab, and trastuzumabwas continued for 1 year. Median
follow-up was 4 years.
INTERVENTIONS Treatment consisted of weekly 80-mg/m2 doses of paclitaxel administered
concurrently with trastuzumab intravenously for 12 weeks, followed by trastuzumab
monotherapy for 39 weeks. During themonotherapy phase, trastuzumab could be
administered weekly 2-mg/kg or every 3 weeks as 6-mg/kg. Radiation and hormone therapy
were administered per standard guidelines after completion of the 12 weeks of
chemotherapy. Patient LVEF was assessed at baseline, 12 weeks, 6months, and 1 year.
MAIN OUTCOMES ANDMEASURES Cardiac safety data, including grade 3 to 4 left ventricular
systolic dysfunction (LVSD) and significant asymptomatic LVEF decline, as defined by our
study, were reported.
RESULTS Overall, 2 patients (0.5%) (95% CI, 0.1%-1.8%) developed grade 3 LVSD and came
off study, and 13 (3.2%) (95% CI, 1.9%-5.4%) had significant asymptomatic LVEF decline,
11 of whom completed study treatment. Median LVEF at baseline was 65%; 12 weeks, 64%;
6months, 64%; and 1 year, 64%.
CONCLUSIONS AND RELEVANCE Cardiac toxic effects from paclitaxel with trastuzumab,
manifesting as grade 3 or 4 LVSD or asymptomatic LVEF decline, were low. Patient LVEF was
assessed at baseline, 12 weeks, 6months, and 1 year, and our findings suggest that LVEF
monitoring during trastuzumab therapy without anthracyclines could be simplified for many
individuals.
JAMA Oncol. 2016;2(1):29-36. doi:10.1001/jamaoncol.2015.3709
Published online November 5, 2015.
Editorial page 21
Supplemental content at
jamaoncology.com
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: Chau Dang,
MD, Memorial Sloan Kettering Cancer
Center, 1275 York Ave, New York, NY
10065 (dangc@mskcc.org).
Research
Original Investigation
(Reprinted) 29
Downloaded From: http://jamanetwork.com/ by a Indiana University School of Medicine User  on 11/30/2016
Copyright 2016 American Medical Association. All rights reserved.
I n the United States, breast cancer is themost common fe-male cancer and the second most common cause of can-cer death in women.1 Amplification or overexpression of
the human epidermal growth factor receptor 2 (ERBB2, for-
merly HER2 or HER2/neu) oncogene is present in approxi-
mately20%to25%ofprimary invasivebreast cancers.2Trastu-
zumab has demonstrated a significant improvement in
outcomes of women with early-stage breast cancer in key
adjuvant trials, but most of these trials contained an anthra-
cycline-based therapy followedby trastuzumabwith orwith-
out a taxane in women with either node-positive or node-
negative,high-riskbreast cancer (usuallydefinedas tumorsize
>1 cm or >2 cm).3-8 However, several studies from the pretra-
stuzumab era suggest a higher risk of recurrence for patients
with ERBB2-positive, node-negative tumors compared with
those with ERBB2-negative tumors of the same size.9-11 Re-
cent retrospective studies have demonstrated a benefit from
the combination of chemotherapy and trastuzumab in those
withnode-negative breast cancer and a time trend increase in
the use of these agents.12-14
The most significant toxic effect of trastuzumab, espe-
cially following an anthracycline-based therapy, is sympto-
matic congestive heart failure (CHF) that has been reported
from 0.9% to 4% and significant asymptomatic cardiac
decline ranging from 4% to 19% in clinical trials.3-8,15-19
After the anthracycline phase, most symptomatic CHF and
asymptomatic left ventricular ejection fraction (LVEF)
decline occurred during the period of trastuzumab
administration.3-8,15-19 Unlike cardiac toxic effects associ-
ated with anthracyclines, LVEF decline following trastu-
zumab therapy is not dose related and is considered to be
mostly reversible.20 Most previous clinical trials involving
trastuzumab included patients who were exposed to anthra-
cyclines, but it is not clear how much the anthracyclines
contributed to trastuzumab-mediated cardiac dysfunction.
To reduce cardiac and noncardiac toxic effects with the
hope of maintaining a high degree of effectiveness, we con-
ducted a trial of weekly paclitaxel with trastuzumab in
patients with early-stage ERBB2-positive breast cancer. The
overall study results have been previously reported, and
this article highlights the detailed cardiac data that have
been collected.21
Methods
Thiswas a secondary analysis of anuncontrolled, single group
study across 14 medical centers of weekly administration of
paclitaxel with trastuzumab in patients with node-negative,
ERBB2-positivebreast cancer.21Thestudywasapprovedby the
institutional review board at each site, and written informed
consent was obtained from each patient. Race, ethnicity, and
sexwere defined by each patient to demonstrate the enrolled
patient population (Table 1).
The primary endpoint was disease-free survival. Grade 3
and 4 left ventricular systolic dysfunction (LVSD), as defined
by theNationalCancer InstituteCommonToxicityCriteriaAd-
verse Events (NCI CTCAE) version 3.0, was a secondary end-
point. Grade 3 LVSD is symptomatic CHF responsive to inter-
vention, and grade 4 LVSD is refractory CHF. Other adverse
cardiac events were also classified per the NCI CTCAE grad-
ing system version 3.0. This study protocol required longitu-
dinalassessmentof leftventricularsystolic functionusingLVEF
quantified by transthoracic echocardiogram (ECHO) or radio-
nuclide multigated acquisition scan (MUGA) at baseline, 12
weeks, 6 months, and 1 year after starting protocol-specified
therapy.Patientswhowentoff treatmentearlyduetoCHFwere
required to have follow-up LVEF assessments 3, 6, and 12
months after the CHF event.
The study population was defined as all patients who re-
ceived any amount of protocol therapy. Diagnosis of grade 3
to 4 LVSD (ie, symptomatic CHF) during protocol therapy re-
quired cessation of trastuzumab therapy. For these patients,
we reported the registration date, protocol therapy starting
date, off-treatment date, number of cycles administered, and
LVEF percentages. Trastuzumab was interrupted for asymp-
tomatic declines in LVEF within the following 2 categories: a
10% to 15% decrease from a baseline LVEF that was less than
the local lower limit of normal for LVEF, or a decrease greater
than or equal to 16% (eTable 1 in the Supplement). All pa-
tients with interval development of asymptomatic LVEF de-
cline requiring interruption of trastuzumab underwent re-
peated LVEF assessment using the same modality after an
interval of 4 weeks. If the LVEF did not recover to a “con-
tinue” category asdefinedby studyguidelines (eTable 1 in the
Supplement), and if 2 consecutive holds were required, then
thepatientwouldbewithdrawn fromstudy treatment. Inves-
tigatorswerestronglyurged toscheduleMUGAscansorECHOs
at the same radiology facilitywhere thepatient’s baseline scan
was done, and we used the baseline LVEF to compare with
LVEF assessed at 12 weeks, 6 months, and 1 year. The inci-
dence of grade 3 to 4 LVSD was determined with the 95% CI.
Statistical Analysis
Theplannedsample sizeof400wasbasedon theprimaryend-
pointofdisease-freesurvival.Thestatisticaldesignandsample
size considerationshavebeendescribed in aprevious study.21
The incidence of grade 3 to 4 LVSD and asymptomatic LVEF
declinewere secondary endpoints. For this analysis, the inci-
dence of grade 3 to 4 LVSD and asymptomatic LVEF decline
At a Glance
• We evaluated cardiac toxic effects of 406 patients receiving
paclitaxel and trastuzumab for early-stage ERBB2-positive breast
cancer.
• Overall, 2 patients (0.5%) (95% CI, 0.1%-1.8%) developed grade
3 left ventricular systolic dysfunction (LVSD).
• Thirteen patients (3.2%) (95% CI, 1.9%-5.4%) had significant
asymptomatic left ventricular ejection fraction (LVEF) decline,
11 of whom completed study treatment.
• Median LVEF was 65% at baseline; 64%, 12 weeks; 64%,
6months; and 64%, 1 year.
• Cardiac toxic effects from paclitaxel with trastuzumab,
manifesting as grade 3 to 4 LVSD or asymptomatic LVEF decline,
were low.
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were analyzed as binary outcomes. Rates of grade 3 to 4 LVSD
and asymptomatic LVEFdecline and95%CIswere calculated
using theWilsonmethod.22Withaplannedsample sizeof400
patients, the estimated half-width of the Wilson 95% CI was
0.5%with0cases of grade 3 to4LVSDobserved; 1.1%, 4; 1.4%,
8; 1.7%, 12; 2.0%, 16; and 2.2%, 20.
Toexplore theassociationbetweenbaselinecharacteristics
and occurrence of cardiac toxic effects, relative risks (RR), and
95%CIswerecalculatedusingrobustvarianceestimates.23,24Sta-
tisticalanalyseswereperformedusingSAS9.3(SASInstituteInc)
andR version 2.6.1 (RevolutionAnalytics) statistical software.
Patients
Eligible patients had node-negative ERBB2-positive (immu-
nohistochemistry 3-positive or fluorescence in situhybridiza-
tion-amplified with ratio 2.0 or greater) breast cancer with a
tumor 3 cm or smaller. Patients with a micrometastasis in a
lymphnodewere later allowedwith studyamendmentonMay
19, 2009. Patients with a baseline LVEF less than 50%, his-
tory of myocardial infarction, CHF, uncontrolled hyperten-
sion (systolic blood pressure >200 mm Hg or diastolic blood
pressure >100mmHg), or hemodynamically significant peri-
cardial effusion were excluded from this study.
Treatment
Treatment consisted of weekly 80-mg/m2 doses of paclitaxel
administeredconcurrentlywith trastuzumab intravenously for
12weeks, followedby trastuzumabmonotherapy for 39weeks
(eFigure2 in theSupplement).During themonotherapyphase,
trastuzumab could be administeredweekly 2-mg/kg or every
3 weeks 6-mg/kg. Radiation and hormone therapy were ad-
ministered per standard guidelines after completion of the 12
weeks of chemotherapy.
Results
FromOctober9, 2007, toSeptember3, 2010,410patientswere
enrolled and 406 started protocol therapy. All 406 patients
completed treatment as of September8, 2011. Themedian fol-
low-upwas 4 years. Themedian patient agewas 55 years, 118
(29%) patients had a history of hypertension, and 30 (7%) pa-
tients had a history of diabetes (Table 1). The majority of pa-
tientswithhypertension (84%)anddiabetes (83%)wereat least
50 years of age (Table 2). There were 356 (88%) patients who
completed about a year of protocol therapy and 50 (12%)who
did not. The 50patientswhodid not complete about a year of
protocol therapywere takenoff the study for the following rea-
sons: 2 for grade 3 LVSD; 2, persistent grade 2 LVSD; 1, grade 3
arrhythmia; 1, grade 3 sinus tachycardia; 1, grade 2 palpita-
tions; 42, noncardiac reasons; and 1, reason unknown. Over-
all, 7 (1.7%) patients discontinued protocol treatment for car-
diovascular reasons but only 4 (1.0%) patients discontinued
due to LVSD (95% CI, 0.3%-2.5%).
Changes in LVEF
Baseline LVEF values were between 50% and 55% in 40
(10%) patients, and greater than 55% in 366 (90%) patients
(eTable 2 in the Supplement). Of the 40 patients with base-
line LVEF of less than or equal to 55%, 26 (65%) were at least
50 years of age. Overall, the majority of patients had a
decline in LVEF from baseline of less than 10% (84% at 12
weeks; 80%, 6 months; and 74%, 1 year), and only a minor-
ity of patients had a decline in LVEF from baseline of 10% to
15% (7% at 12 weeks; 9%, 6 months; and 9%, 1 year) and
greater than or equal to 16% (<1% at 12 weeks; 1%, 6 months;
and 2%, 1 year). The LVEF values were well preserved
throughout treatment as median (range) 65% (50%-81%) at
baseline; 64% (45%-81%), 12 weeks; 64% (45%-83%), 6
months; and 64% (41%-90%), 1 year (Table 3).
Grade 3 to 4 LVSD
Out of 406 patients who started protocol therapy, 2 (0.5%)
patients developed grade 3 LVSD (95% CI, 0.1%-1.8%), one
of whom was a woman in her 60s taking medications for
hyperlipidemia on study entry and who had developed
symptomatic CHF 11 months after starting treatment. Her
LVEF assessments were 55% at baseline; 54%, 12 weeks;
60%, 6 months; and 37%, 11 months. She did not resume
trastuzumab per study stipulation. Subsequent treatment
with lisinopril achieved full resolution of CHF symptoms
and a restoration of LVEF to 60% at 16 months and 66% at
27 months (eTable 3 and eFigure 1 in the Supplement). The
other patient was a woman in her 50s taking a β-blocker for
a diagnosis of arrhythmogenic right ventricular dysplasia.
Her LVEF was 66% at baseline and 61% at 12 weeks, and it
declined to 50% at 6 months, which coincided with the
onset of symptoms of CHF. Trastuzumab therapy was termi-
nated. Medical management with a regimen of furosemide,
ramipril, and carvedilol was initiated, and she became
asymptomatic with subsequent LVEF assessments of 51% at
Table 1. Patient Characteristics
Characteristic No.
Total patients 406
Age, median (range), y 55 (24-85)
Sex, No. (%)
Male 1 (<1)
Female 405 (100)
Race, No. (%)
White 351 (86)
African American 28 (7)
Asian 11 (3)
Other 16 (4)
Ethnicity, No. (%)
Hispanic or Latino 9 (2)
Non-Hispanic 374 (92)
Ethnicity not known 23 (6)
History of hypertension, No. (%)
Yes 118 (29)
No 288 (71)
History of diabetes, No. (%)
Yes 30 (7)
No 376 (93)
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7 months; 54%, 8 months; and 56%, 18 months (eTable 3
and eFigure 1 in the Supplement). Both patients were medi-
cally managed by their cardiologists for CHF. Overall, these
2 patients had at least 2 potential risk factors for cardiac
dysfunction. Both patients were older than 50 years of age,
and one had baseline LVEF of only 55% while the other had
arrhythmogenic right ventricular dysplasia due to fatty infil-
tration of the right ventrical. Most patients with arrhythmo-
genic right ventricular dysplasia will have left ventricular
involvement over time resulting in biventricular failure.
Incidence of Asymptomatic Decrease in LVEF
Overall, 13 (3.2%)patients (95%CI, 1.9%-5.4%)experiencedan
asymptomatic LVEF decline significant enough to require
trastuzumab interruption per study criteria (eTable 3 in the
Supplement).Twopatientsdiscontinuedprotocol therapy.An-
other patient had significant asymptomatic LVEFdecline that
did not recover during the 4-week study timeframe. How-
ever, she was not taken off study and trastuzumab was con-
tinued,whichwasa studyviolation.Of the3patientswithper-
sistentasymptomatic (ie, lasting≥4weeks)LVEFdecline (grade
2LVSD), 2wereat least 50yearsof ageandhadabaselineLVEF
of only 55%. One of these patients also had hypertension and
diabetes, was on cardiac medications (amlodipine and aten-
olol) at baseline for hypertension, and did not have addi-
tional medications at the time of trastuzumab cessation. The
otherpatienthadcardiacmedications (lisinopril, losartan, and
carvedilol) added (eTable 3 in the Supplement).
Of the 10 remaining patients with significant asymptom-
atic LVEF decline during treatment, 6 had already completed
1 year of therapy when a significant asymptomatic LVEF
decline occurred at the end of treatment, and 2 patients had
cardiac medications added. Because these patients had com-
pleted therapy already, any follow-up LVEF monitoring was
at the physician’s discretion. The other 4 patients experi-
enced significant asymptomatic LVEF decrement and recov-
ered appropriately before completing 1 year of therapy. Only
1 patient had cardiac medication added, but the other 3
patients did not. Of these 10 patients, only 3 patients had 2
cardiovascular risk factors (≥50 years of age and hyperten-
sion), and 2 patients were taking antihypertensive medica-
tion at baseline and 1 was not. Of note, in the 10 patients, all
but 1 patient had baseline LVEF greater than 55%. Overall, in
these 13 (3.2%) patients with significant asymptomatic LVEF
decline, only 5 had at least 2 cardiovascular risk factors, and
notably, only 3 had baseline LVEF of 55%. We performed an
exploratory analysis to assess the relationship between
baseline characteristics and cardiac outcomes, and there
appeared to be a correlation between a low baseline LVEF of
55% or less and higher incidence of significant asymptom-
atic LVEF decline or grade 3 to 4 LVSD (risk ratio [RR], 0.30;
95% CI, 0.10-0.90; P = .05) (Table 4).
Table 2. Distribution of Age in PatientsWith Hypertension and DiabetesMellitus
Characteristic
Patients
All Hypertension Diabetes Mellitus
Patients, No. 406 118 30
Age, median (range), y 55 (24-85) 61 (40-85) 59 (40-76)
Age group, No. (%), y
<50 132 (33) 19 (16) 5 (17)
50-59 137 (34) 32 (27) 10 (33)
60-69 96 (24) 45 (38) 11 (37)
>70 41 (10) 22 (19) 4 (13)
Table 3. Summary of LVEF at Protocol-Specified Time Points and Changes FromBaseline Values
Characteristic
No. (%)
Baseline 12 weeks 6 mo 1 y
LVEF reduction from baseline
<10% 343 (84) 325 (80) 302 (74)
10%-15% 29 (7) 36 (9) 35 (9)
≥16% 2 (<1) 5 (1) 7 (2)
Required, not evaluateda 7 (1) 9 (2) 22 (5)
Not requiredb 25 (6) 31 (8) 40 (10)
LVEF level, %
Median (range) 65 (50-81) 64 (45-81) 64 (45-83) 64 (41-90)
Abbreviation: LVEF, left ventricular ejection fraction.
a Patients for whom cardiac evaluation was required but reported as not
completed were counted as required but not evaluated.
b Cardiac evaluations were not required for patients who went off protocol
therapy due to noncardiac toxic effects. Assessments after the off-treatment
visit for patients who went off treatment before completing 1-year
protocol–specified therapy due to noncardiac toxic effects were counted as
not required.
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Discussion
This regimen of paclitaxel and trastuzumab without an
anthracycline has already demonstrated exceptional out-
comes with 3-year disease-free survival exceeding 98.7%.21
In this analysis, we also demonstrate that it is well-tolerated,
with incidence of grade 3 to 4 LVSD (CHF) of only 0.5% (95%
CI, 0.1%-1.8%). This is consistent with the data from the
study by Slamon et al (BCIRG 006)7,25 and the phase II trial
by Jones et al26 on docetaxel and cyclophosphamide with
trastuzumab.7,26 The incidence of grade 3 to 4 LVSD for
both studies was 0.4% with a nonanthracycline taxane–
trastuzumab combination.5,26 In this study, the 2 patients
who developed grade 3 LVSD had at least 2 cardiovascular
risk factors and experienced CHF during active therapy at 6
and 11 months, respectively, with subsequent recovery. Only
13 (3.2%) (95% CI, 1.9%-5.4%) of 406 patients demonstrated
a significant asymptomatic decline in LVEF requiring trastu-
zumab interruption per protocol. Of these 13 patients, 3 had
persistent LVEF decline, and 2 patients were removed from
study while 1 continued therapy, which was a study viola-
tion. The remaining 10 patients completed trastuzumab
therapy as planned. In these 13 patients, 5 had at least 2 car-
diovascular risk factors.
These results compared favorably with the combined
analysis of NSABP B-31 and N9831 in the study by Romond et
al,3 in which 14.2% of patients did not complete 1 year of
trastuzumab due to significant asymptomatic LVEF
deterioration.3 The low incidence of LVEF decline in our
study was most likely attributable to the absence of the
anthracycline. In addition, over the last decade, there has
been a higher threshold to stop trastuzumab as a result of
asymptomatic left ventricular dysfunction given the growing
appreciation of the benefits of trastuzumab therapy and col-
laboration between cardiologists and oncologists.27 In our
study, 88% of patients completed 1 year of therapy, includ-
ing the patients who resumed therapy after a temporary
interruption for asymptomatic LVEF decline. This was favor-
able when compared with the phase II study by Jones et al26
in which only 82% of patients completed the full year of
therapy.
Previous data suggest that late cardiac toxic effects from
trastuzumab therapy is rare in oncology clinical trials. Seven-,
8-, and 9-year follow-up data from the National Surgical Ad-
juvantBreast andBowelProject (NSABP)B-31,28HerceptinAd-
juvant (HERA)6 trial, and North Central Cancer Treatment
Group (NCCTG) N 9831 trial,15 respectively, described no in-
crease in the New York Heart Association class III to IV heart
failure and/or cardiacdeath rate,witheventsoccurringmainly
during active therapy.6,28 In addition, cardiac events re-
ported for 2 trials of dose-dense chemotherapy with anti-
ERBB2 agents occurred mainly during active therapy, with
5- and7-year follow-updata, respectively.19Whenextrapolat-
ing the information from these data to our study with a me-
dian follow-up of 4 years, it is likely that the 0.5% incidence
ofgrade3LVSDwithpaclitaxelandtrastuzumabwillnotchange
over time with a longer follow-up.
In contrast, recent claims-based reports have shown that
heart failure and/or cardiomyopathy rates exceeded those
reported by other prospective studies with long-term
follow-up durations.6,15,19,28 For example, Bowles et al29
conducted a population-based retrospective cohort study of
12 500 women with invasive breast cancer who were treated
with no chemotherapy, anthracycline, trastuzumab, anthra-
cycline and trastuzumab, or other chemotherapies. In this
study, only 0.9% of patients received trastuzumab without
an anthracycline. At 1, 3, and 5 years, the respective rates of
heart failure and/or cardiomyopathy were 3.6%, 7.8%, and
12.1% with trastuzumab without an anthracycline. These
findings were similar to those reported in articles by Chen et
al,30 Chavez-MacGregor et al,31 and Ezaz et al.32 The patient
populations in these retrospective studies were much older,
with mean ages ranging from 60 to 76 years old.29-32 The
Table 4. Cross-tabulation of Baseline Characteristics and Grade 3 to 4 LVSD or Asymptomatic LVEF Decline
Characteristic
Total
Patients, No.
No. (%)
Relative Risk
(95% CI) P Value
No Cardiac
Toxic Effects
Grade 3 to 4 LVSD
or Asymptomatic
LVEF Decline
Age at study entry, y
<50 132 126 (95) 6 (5) NA
.58
≥50 274 265 (97) 9 (3) 0.72 (0.26-1.99)
Baseline LVEF, %
≤55 y 40 36 (90) 4 (10) NA
.05
>55 y 366 355 (97) 11 (3) 0.30 (0.10-0.90)
History of hypertension
Yes 118 113 (96) 5 (4) NA
.77
No 288 278 (97) 10 (3) 0.82 (0.29-2.35)
History of diabetes
Yes 30 27 (90) 3 (10) NA
.09
No 376 364 (97) 12 (3) 0.32 (0.10-1.07)
Abbreviations: LVEF, left ventricular
ejection fraction; LVSD, left
ventricular systolic dysfunction;
NA, not applicable.
Cardiac Outcomes for Patients on Paclitaxel and Trastuzumab Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology January 2016 Volume 2, Number 1 33
Downloaded From: http://jamanetwork.com/ by a Indiana University School of Medicine User  on 11/30/2016
Copyright 2016 American Medical Association. All rights reserved.
higher rates in these retrospective studies, when compared
with well-designed prospective trials, could be due to an
overestimation of the true risk of cardiac toxic effects in
claims-based studies and/or that the patients in prospective
clinical trials were healthier and younger by selection.
Finally, retrospective claims-based data were also limited
due to a lack of rigorous adjudication of events.
Risk factors associated with trastuzumab-related cardiac
toxic effects include anthracycline exposure and age 50
years and older.28,33-36 Our exploratory analysis suggests an
association between a low baseline LVEF 55% or less and
incidence of asymptomatic LVEF decline and grade 3 to 4
LVSD. In addition, multivariate analyses identified border-
line low LVEF of less than 55%, hypertension, and high body
mass index as predisposing risk factors for trastuzumab-
induced cardiac toxic effects, whereas influences of diabe-
tes, valvular heart disease, and coronary artery disease were
not statistically significant.28,34,36,37 Concurrent trastu-
zumab with radiation does not increase cardiac toxic
effects.28,36,38 In our study of 406 patients, 40 (10%) had
baseline LVEF of 55% or less and 26 (6%) had baseline LVEF
of 55% or less and were 50 years of age or older. Additionally,
118 (29%) patients had a history of hypertension, 30 (7%)
had diabetes, and the majority of patients with hypertension
(84%) and diabetes (83%) were at least 50 years of age. Given
the low incidence in our study of cardiac dysfunction where
patients did not receive an anthracycline, serial monitoring
may be reserved for patients considered at a higher risk of
developing cardiac toxic effects, as well as those with signs
and symptoms of CHF or other cardiac symptoms. If this
approach to screening was implemented in this study, many
LVEF assessments would have been avoided for the majority
of asymptomatic patients with baseline LVEF greater than
55% without coexisting cardiovascular risk factors. The
extent to which such rationalized LVEF surveillance might
reduce interruption of trastuzumab, reduce cost, and have an
effect on cardiovascular and cancer prognoses requires inves-
tigation. Moreover, we advocate for closer collaboration
between cardiologists and oncologists in determining the
best strategies in identifying patients who are at risk of devel-
oping heart failure such that the patient can complete the
course of trastuzumab therapy without interruption.
This study had some limitations. First, LVEF quantifica-
tions by ECHOs orMUGAs did not follow a standard protocol,
and a core laboratorywasnot used for analyses. Thus, data on
interobserved and intraobservedvariability and reproducibil-
ity of LVEF reports in this study were lacking. However, this
limitationwas common tomany chemotherapy trials that in-
cluded cardiovascular safety endpoints. Second, certain pa-
tient groups that were considered at higher risk for trastu-
zumab-associated cardiac toxic effects, such as those with a
history of myocardial infarction or CHF, were excluded from
this study. As such, study findings and recommendations for
a reduced number of LVEF assessments cannot be general-
ized to suchpatients.Third, it is increasingly clear fromemerg-
ing cardiac literature that LVEFmay not be the bestmarker of
cardiac contractility.39 Fourth, data for certain cardiovascu-
lar risk factors such as hyperlipidemia, cerebrovascular dis-
ease, and prior coronary revascularizations were not consis-
tently collected. Fifth,management of deteriorations in LVEF
duringtreatmentwasdirectedat thephysician’sdiscretion,and
variation in management likely influenced likelihood of re-
covery in LVEF.
Conclusions
There was a low incidence of grade 3 to 4 LVSD (0.5%) and
asymptomatic deteriorations in LVEF (3.2%) during treat-
ment with paclitaxel (0.5%) and trastuzumab (3.2%). The fa-
vorable cardiovascular safetyprofileof trastuzumab in thisno-
nanthracycline setting suggests thatbaselineLVEFassessment
maybe sufficient for themajority of patients,with serial LVEF
assessments reserved for patients considered at a higher risk
for cardiac toxic effects. A prospective trial to include a uni-
form assessment and management of cardiovascular risk
factors, as well as a central review of LVEF data in patients
receivinganonanthracyclineregimenwithanti-ERBB2therapy,
will be needed to help further define which patients may re-
quire less intensive LVEFmonitoring.
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